» Articles » PMID: 16614305

Activation of Myocardial Contraction by the N-terminal Domains of Myosin Binding Protein-C

Overview
Journal Circ Res
Date 2006 Apr 15
PMID 16614305
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Myosin binding protein-C (MyBP-C) is a poorly understood component of the thick filament in striated muscle sarcomeres. Its C terminus binds tightly to myosin, whereas the N terminus contains binding sites for myosin S2 and possibly for the thin filament. To study the role of the N-terminal domains of cardiac MyBP-C (cMyBP-C), we added human N-terminal peptide fragments to human and rodent skinned ventricular myocytes. At concentrations >10 micromol/L, the N-terminal C0C2 peptide activated force production in the absence of calcium (pCa 9). Force at the optimal concentration (80 micromol/L) of C0C2 was approximately 60% of that in maximal Ca2+ (pCa 4.5), but the rate constant of tension redevelopment (ktr) matched or exceeded (by up to 80%) that produced by Ca2+ alone. Experiments using different N-terminal peptides suggested that this activating effect of C0C2 resulted from binding by the pro/ala-rich C0-C1 linker region, rather than the terminal C0 domain. At a lower concentration (1 micromol/L), exogenous C0C2 strongly sensitized cardiac myofibrils to Ca2+ at a sarcomere length (SL) of 1.9 microm but had no significant effect at SL 2.3 microm. This differential effect caused the normal SL dependence of myofibrillar Ca2+ sensitivity to be reduced by 80% (mouse myocytes) or abolished (human myocytes) in 1 micromol/L C0C2. These results suggest that cMyBP-C provides a regulatory pathway by which the thick filament can influence the activation of the thin filament, separately from its regulation by Ca2+. Furthermore, the N-terminal region of cMyBP-C can influence the SL-tension (Frank-Starling) relationship in cardiac muscle.

Citing Articles

Cardiac length-dependent activation driven by force-dependent thick-filament dynamics.

Lewalle A, Milburn G, Campbell K, Niederer S Biophys J. 2024; 123(18):2996-3009.

PMID: 38807364 PMC: 11428202. DOI: 10.1016/j.bpj.2024.05.025.


iPSC-cardiomyocytes in the preclinical prediction of candidate pharmaceutical toxicity.

Lee T, Coles J, Maynes J Front Pharmacol. 2024; 15:1308217.

PMID: 38482053 PMC: 10933010. DOI: 10.3389/fphar.2024.1308217.


Hypertrophic cardiomyopathy in carriers in aging.

Ananthamohan K, Stelzer J, Sadayappan S J Cardiovasc Aging. 2024; 4(1.

PMID: 38406555 PMC: 10883298. DOI: 10.20517/jca.2023.29.


The contribution of N-terminal truncated cMyBPC to in vivo cardiac function.

Dominic K, Choi J, Holmes J, Singh M, Majcher M, Stelzer J J Gen Physiol. 2023; 155(6).

PMID: 37067542 PMC: 10114924. DOI: 10.1085/jgp.202213318.


cMyBP-C ablation in human engineered cardiac tissue causes progressive Ca2+-handling abnormalities.

de Lange W, Farrell E, Hernandez J, Stempien A, Kreitzer C, Jacobs D J Gen Physiol. 2023; 155(4).

PMID: 36893011 PMC: 10038829. DOI: 10.1085/jgp.202213204.